The latest innovations in healthcare, including ambient AI for virtual clinics, a drug manufacturing platform, an investment in a global AI lab, a new CQC compliance toolkit, preventative diagnostics in the North, non-surgical knee treatments and specialist health play innovations.
Doctor Care Anywhere and Tandem Health partner for AI-powered virtual care
Doctor Care Anywhere, one of the UK’s largest private telehealth providers, has announced a partnership with Tandem Health to integrate a clinical AI operating system directly into its virtual primary care platform.
The collaboration aims to reduce the administrative burden on clinicians by using ambient voice technology to automate clinical documentation in real-time.
The Tandem AI system is designed to listen during virtual consultations, automatically capturing the dialogue and generating structured medical records. This allows clinicians to remain focused on the patient rather than losing up to 40% of their time to manual note-taking.
The platform is fully aligned with UK healthcare governance, including NHS Ambient Voice Technology guidance and DCB 160 clinical safety standards, and integrates with Doctor Care Anywhere’s existing Microsoft Dynamics-based electronic health records.
“Clinicians shouldn’t be losing 40% of their time to documentation,” said Lukas Saari, chief executive and co-founder of Tandem Health.
Micropore Technologies designs new platform to accelerate drug manufacturing
Teesside-based Micropore Technologies has designed a next-generation integrated emulsification platform designed to streamline the journey of complex therapeutics from the lab to clinical trials.
The company’s technology allows for high-precision particle engineering with a low-shear approach that protects the integrity of delicate biologics while maintaining strict control over particle size.
Dubbed HORIZON, it aims to solve a bottleneck in drug development: the trial-and-error phase of scaling up from r&d to commercial production. Because the system keeps the core technology and control architecture constant as it moves to larger vessels, technical continuity is guaranteed. This de-risks the manufacturing process, reduces material waste through a low-holdup design, and ensures that the rigorous standards established during early discovery are replicated at volume.
“The launch… marks a fundamental shift in how complex formulations move from the laboratory to commercial production,” said Kay Hussain, chief executive of Micropore Technologies. The platform, which includes a compact mini version for pilot scales and an industrial one system for high throughput, has already been trialled by global pharmaceutical leaders and the Centre for Process Innovation (CPI).
Cera launches AI lab to tackle global care crisis
Cera, the UK’s largest domiciliary care provider, has launched the world’s first dedicated AI lab for the care sector. The initiative is designed to build, prove, and license high-impact AI tools – ranging from robotics to agentic AI – to healthcare providers worldwide. By automating administrative and routine tasks, the lab aims to solve the chronic productivity and accessibility challenges facing global health systems as ageing populations outpace the available workforce.
The firm has confirmed that the investment is “eight-figure” but has not provided further details.
The AI lab builds on Cera’s dataset of more than 300 billion health insights gathered during 2.5 million monthly home visits. Cera says it has already demonstrated the efficacy of its technology in the UK, where its predictive algorithms have halved avoidable hospital admissions, and it claims to have saved the government over £1 billion.
To drive this new venture, Cera has hired what it is calling Entrepreneurs in Residence to work alongside data scientists and clinical leaders to identify frontline bottlenecks and develop licensed solutions at pace.
“The alternative to AI isn’t human care. For millions right now, the alternative is no care at all,” said Cera founder and chief executive Ben Maruthappu.
The UK Government has backed the move, with AI minister Kanishka Narayan saying that Cera is “proof that AI can power the transformation of healthcare systems around the world”. The lab’s current portfolio includes AI recruitment agents that double hiring volumes and care robots that increase provider capacity by 20% by supporting patients with nutrition and medication reminders.
Semble introduces CQC companion
Healthcare technology company Semble has introduced the CQC Companion, an online toolkit designed to help private healthcare providers navigate Care Quality Commission (CQC) inspections.
“Our goal is to make compliance feel manageable,” said Jenny Williams, senior clinical product manager at Semble and a former GP. “We want providers to spend less time deciphering requirements and more time with patients.”
The launch comes as record numbers of clinicians transition from the NHS into private practice – a move often accompanied by significant regulatory hurdles. Developed alongside CQC specialists and medical directors, the toolkit translates complex governance requirements into a practical, step-by-step roadmap.
The companion features an hour-by-hour breakdown of inspection day, self-auditing advice, and an online guide containing more than 100 checkpoints across nine clinical segments. By demystifying the process, the tool aims to ensure that “excellent clinical care” is accurately reflected in the governance and documentation that inspectors require. The toolkit is part of Semble’s broader effort to streamline practice management, which currently supports over 1,600 healthcare businesses across 80 specialities.
The initiative specifically targets the administrative burnout often associated with compliance; research indicates that 66% of clinicians work outside scheduled hours, frequently citing regulatory paperwork as a primary stressor.
Cocoon launches pioneering preventative healthcare clinic in Yorkshire
Harrogate-based healthcare provider Cocoon has launched one of the North of England’s first science-led private prevention clinics.
Originally established in 2024 as a women’s wellness and pregnancy centre, the clinic is pivoting toward a broader early-detection and long-term health screening model. The move addresses growing public anxiety over NHS diagnostic wait times and a rising demand for baseline health data before patients invest in reactive wellness interventions.
The new clinic combines advanced diagnostics – including ultrasound imaging, metabolic profiling, and cardiovascular assessments – with what founder Sam Naughton describes as “soul-led care.” By offering premium surroundings and zero waitlists, Cocoon aims to provide a high-end alternative to the London-centric private market. The expansion is bolstered by the appointment of consultant radiologist Adam Culverwell as medical director, who will oversee cancer screening and diagnostic imaging pathways.
“This expansion is a direct response to what so many people are feeling right now – anxiety around not knowing,” said Naughton. The clinic’s model focuses on identifying changes before a patient becomes symptomatic, which can significantly widen treatment options and improve long-term outcomes.
A viable non-surgical alternative for NHS knee osteoarthritis patients
A white paper has been published by London-based Contura Orthopaedics, detailing the potential for a pioneering injectable hydrogel to transform the NHS treatment pathway.
The paper argues that Arthrosamid, a 2.5% polyacrylamide hydrogel, could offer a long-lasting, minimally invasive alternative to total knee replacement surgery, potentially saving the healthcare system millions in surgical and recovery costs.
It catalogues extensive clinical evidence, including recent five-year and 10-year safety data, which supports the hydrogel’s ability to provide sustained pain relief. Current research led by Martyn Snow at the Robert Jones and Agnes Hunt Orthopaedic Hospital has already shown a 70% clinically meaningful improvement in patients 12 months after a single injection.
Ongoing trials are now exploring phenotypes of osteoarthritis to predict which patients will respond best to the treatment, with the goal of achieving response rates in the high 90th percentile.
“At the moment, patients in need of Arthrosamid are having to pay for it privately, but ultimately, that’s not our goal,” said the firm’s chief executive, Rakesh Tailor.
The firm reported positive results from its LUNA trial at the end of last year. It has also released a digital tool designed to help healthcare professionals create and share personalised rehabilitation plans for patients with knee osteoarthritis.
Starlight and Noah’s Ark Children’s Hospice complete partnership
Health play charity Starlight and Noah’s Ark Children’s Hospice have announced the completion of a three-year partnership aimed at strengthening specialist play provision for children with life-shortening and life-threatening conditions.
Through a funded programme of mentoring and training, Starlight has equipped the hospice’s specialist play team in North London with new tools – including LEGO-based therapy and baby massage – to help seriously unwell children communicate, cope with clinical anxiety, and express themselves.
The partnership focused on making play a “vital part of care” rather than a luxury. The specialist play team at Noah’s Ark works across clinical and holistic settings, supporting families in the hospice, at home, and in schools. Beyond distraction from medical procedures, the team provides critical support for bereaved families, helping them create special keepsakes such as 3D casts and memory books to cherish the time spent with their babies.
“In a life full of medical equipment and emotional stress, play creates moments where children can simply be children,” said Vikki Kempster, specialist play manager at Noah’s Ark.
